^
Association details:
| Biomarker: | KRAS mutation + STK11 mutation + KEAP1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical characteristics, co-mutations and outcomes of advanced non-small cell lung cancer (NSCLC) patients with KRAS mutations.
Published date:
05/19/2021
Excerpt:
KRAS mt pts with STK11/KEAP1 that were treated with immunotherapy-based regimens had shorter PFS (1.1 vs 7.6 m, p = 0.001) and OS (1.4 vs 90.9 m, p = 0.0007) compared to those treated with chemotherapy alone....Our data shows that pts with KRAS co-mt with STK11/KEAP1 had worse PFS and OS with the addition of immunotherapy compared to chemotherapy alone...
DOI:
10.1200/JCO.2021.39.15_suppl.e21174
